drugset / Trial / NCT00381888
Fondaparinux in Preventing Blood Clots in Patients Undergoing Surgery for Gynecologic Cancer
NaSingle-groupOpen-labelTreatment
Summary
RATIONALE: Fondaparinux may help prevent blood clots from forming in patients who are undergoing surgery for gynecologic cancer. PURPOSE: This phase II trial is studying how well fondaparinux works in preventing blood clots in patients undergoing surgery for gynecologic cancer.
Timeline
- Start
- 2007-01
- Primary completion
- 2009-01
- Completion
- 2009-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fondaparinux | Other / unclassified | 2.5 mg | Subcutaneous |